Legend Biotech Reports 50% 5-Year PFS and 69% OS in CARVYKTI Cohort
Legend Biotech reported CARTITUDE-2 Cohort A 5-year data: 50% of 20 RRMM patients remained progression- and treatment-free; 69.2% were alive at 5 years. Median PFS was 60.5 months; median OS was not reached.Material DetailsContext by AI AnalystThis is late-stage confirmation extending previously po…